ArticleTranslational cancer research2026
High expression of TMEM119 predicts a poor prognosis in gastric cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is one of the most common malignancies worldwide. Transmembrane protein 119 (TMEM119), a member of the transmembrane protein family, has been increasingly linked to cancer progression, with accumulating evidence indicating that its overexpression correlates with poor prognosis in several kinds of human cancers. Nevertheless, the relationship between TMEM119 expression and prognosis in GC patients remains unclear. This study aims to evaluate the association of TMEM119 expression levels and clinical outcomes in GC. Methods: Immunofluorescence was performed to assess TMEM119 expression in GC tissues and matched adjacent non-tumorous tissues. Patients' survival data were collected via scheduled follow-up. Gene expression profiles of TMEM119 and corresponding clinical characteristics of GC patients were obtained from the GSE84437 dataset and the Asian Cancer Research Group (ACRG) database. The Chi-squared test and Fisher's exact test were used to analyze the correlations between TMEM119 expression and clinicopathological characteristics. Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors affecting survival in GC patients. Results: Immunofluorescence staining revealed high expression of TMEM119 in GC tissues. Elevated TMEM119 levels were significantly correlated with poorer prognosis in our institutional cohort of GC patients. This finding was consistently validated in both European and Asian populations, supporting the independence of TMEM119 prognostic value from ethnic variations and underscoring its potential as a cross-population validated prognostic biomarker for GC prognosis. Univariate and multivariate analyses further confirmed that high TMEM119 expression is an independent risk factor for adverse outcomes in GC patients. Conclusions: TMEM119 expression is consistently elevated in GC tissues and is inversely associated with patient prognosis, suggesting its potential value as a prognostic biomarker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.